Zydus Life Science

Zydus Life Science

981.05
+2.45
(0.25%)
Market Cap
98,716.60 Cr
EPS
44.97
PE Ratio
21.17
Dividend Yield
1.12 %
Industry
Healthcare
52 Week High
1,159.35
52 Week Low
795.00
PB Ratio
4.12
Debt to Equity
0.09
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from26 analysts
HOLD
Analysts have suggested that investors can hold this stock
Buy
Buy+30.77 %
+30.77 %
Hold
Hold+50.00 %
+50.00 %
Sell
Sell+19.23 %
+19.23 %

Company News

View All News
Caret
positive
Zydus Lifesciences announced positive results from its Epic-III Phase 2(B)/3 trial of Saroglitazar Magnesium for Primary Biliary Cholangitis. The trial achieved a 48.5% biochemical response rate. The company plans to submit for regulatory approval in Q1 2026.
negative
Zydus Lifesciences announced the passing of Mr. Samir Desai, President-BU Biologics and member of the company's senior management, on August 26, 2025. The company communicated this development to stock exchanges BSE and NSE, noting that Mr. Desai ceases to be part of the senior management following his death.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,594.50
#1 3,82,574.00
33.34
#1 54,729.00
9.71
#1 10,980
-19.84
38.88
6,131.50
1,62,772.10
70.43
9,712.00
18.67
2,191
26.74
42.62
1,589.40
1,28,377.10
23.81
28,409.50
7.12
5,291
9.88
62.50
3,559.80
1,20,479.80
59.64
11,539.40
6.99
1,911
19.91
46.73
1,260.10
1,05,164.30
#1 18.55
33,741.20
16.73
5,725
1.26
51.14
2,471.40
1,02,001.80
53.96
12,744.20
#1 20.90
2,007
-18.14
44.03
981.05
#7 98,716.60
#2 21.17
#4 23,511.00
#3 18.55
#4 4,615
#7 2.60
51.22
1,894.90
86,539.20
23.37
22,909.50
13.74
3,306
#1 51.64
42.37
31,480.00
66,892.80
46.09
6,684.70
9.64
1,414
11.55
37.99
5,303.50
63,411.30
27.88
13,458.30
3.70
2,216
21.39
58.83
Forecast
Actual
Growth Rate
Revenue Growth
18.55 %
Net Income Growth
20.45 %
Cash Flow Change
112.02 %
ROE
0.98 %
ROCE
7.64 %
EBITDA Margin (Avg.)
9.06 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
2,269
2,291
2,286
2,300
2,310
2,232
2,360
2,266
2,479
2,127
3,165
3,206
3,197
2,870
2,875
3,547
3,658
3,429
3,271
3,555
3,672
3,462
3,663
3,645
3,551
3,971
6,106
3,590
3,821
3,989
3,993
4,199
4,890
5,089
4,313
4,403
5,526
6,110
5,182
5,181
6,371
6,622
Expenses
1,792
1,807
1,740
1,768
1,784
1,763
1,841
1,907
2,004
1,909
2,365
2,404
2,399
2,249
2,273
2,738
2,932
2,864
3,009
2,947
3,013
2,724
2,977
2,867
2,916
3,092
2,860
2,895
3,103
3,251
3,319
3,301
4,359
3,650
3,224
3,403
3,903
4,124
3,776
3,882
4,622
4,485
EBITDA
477
484
546
532
526
468
519
359
476
218
800
802
798
621
601
809
726
565
262
608
658
738
686
779
635
879
3,246
695
718
738
673
898
532
1,439
1,089
1,000
1,623
1,986
1,407
1,299
1,749
2,137
Operating Profit %
20 %
20 %
23 %
22 %
21 %
20 %
21 %
15 %
17 %
9 %
25 %
24 %
24 %
19 %
20 %
22 %
19 %
16 %
7 %
17 %
17 %
20 %
17 %
20 %
19 %
21 %
22 %
18 %
17 %
17 %
16 %
21 %
10 %
28 %
24 %
22 %
27 %
32 %
26 %
24 %
27 %
31 %
Depreciation
76
69
73
74
76
84
86
90
114
122
126
147
144
142
148
154
156
172
172
174
179
173
175
176
175
183
177
177
185
181
182
182
179
180
184
195
205
215
234
229
238
238
Interest
16
12
13
12
16
14
15
7
10
22
41
13
15
35
36
46
77
89
90
81
83
68
45
27
23
27
30
31
39
34
35
33
28
18
9
20
35
32
25
32
77
85
Profit Before Tax
426
519
545
537
498
441
435
324
412
154
712
722
724
570
535
672
606
394
122
457
522
588
524
617
526
777
3,135
598
558
673
648
781
484
1,328
1,006
947
1,550
1,900
1,271
1,184
1,672
1,921
Tax
69
51
60
97
-74
36
46
-6
20
9
200
168
125
102
107
150
124
69
28
86
108
102
89
89
-210
135
123
87
105
96
122
149
125
195
203
157
304
417
351
158
428
400
Net Profit
357
468
485
440
572
405
389
331
393
145
513
553
599
467
428
522
482
325
94
371
414
487
435
528
735
643
3,012
511
453
576
526
631
358
1,134
803
790
1,246
1,483
920
1,026
1,244
1,521
EPS in ₹
17.11
22.47
6.46
4.21
5.59
3.89
3.71
3.16
3.77
1.35
4.92
5.31
5.77
4.50
4.08
4.99
4.40
2.97
1.05
3.65
3.83
4.43
4.62
5.15
6.64
5.74
29.32
4.89
3.88
5.06
5.15
6.15
2.93
10.74
7.91
7.80
11.69
14.11
9.06
10.17
11.64
14.58

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
9,047
10,551
15,221
18,065
23,483
23,687
23,885
27,795
25,756
29,281
37,202
Fixed Assets
3,352
3,748
5,755
6,483
12,164
12,231
12,133
12,189
11,521
12,369
13,134
Current Assets
4,227
4,280
6,022
8,230
8,498
8,715
8,716
12,095
10,008
11,420
17,046
Capital Work in Progress
798
951
1,543
1,527
837
742
783
726
1,201
2,423
2,692
Investments
121
416
435
746
674
765
830
3,288
1,547
1,221
6,408
Other Assets
4,776
5,436
7,488
9,310
9,809
9,950
10,139
11,593
11,488
13,269
14,968
Total Liabilities
9,047
10,551
15,221
18,065
23,483
23,687
23,885
27,795
25,756
29,281
37,202
Current Liabilities
3,285
3,461
5,306
6,083
7,343
8,269
7,861
7,827
5,527
5,340
9,042
Non Current Liabilities
1,342
1,255
2,799
3,047
4,461
3,707
1,094
915
541
1,840
1,802
Total Equity
4,421
5,835
7,116
8,936
11,679
11,710
14,930
19,054
19,688
22,102
26,358
Reserve & Surplus
4,149
5,597
6,858
8,642
10,284
10,273
12,890
16,897
17,415
19,729
23,853
Share Capital
102
102
102
102
102
102
102
102
101
101
101

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
178
99
756
-3
-811
399
-91
219
-170
-75
414
Investing Activities
-465
-860
-2,872
-974
-3,977
-1,004
-837
-1,018
1,542
-1,492
-8,377
Operating Activities
994
1,894
1,312
919
1,282
2,932
3,294
2,105
2,689
3,196
6,777
Financing Activities
-351
-935
2,316
52
1,885
-1,528
-2,548
-868
-4,400
-1,779
2,014

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
74.88 %
74.88 %
74.88 %
74.88 %
74.88 %
74.88 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.99 %
74.99 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
5.72 %
5.59 %
7.52 %
7.53 %
7.32 %
7.13 %
DIIs
11.11 %
10.43 %
11.22 %
11.78 %
12.78 %
11.92 %
12.94 %
13.69 %
13.60 %
13.23 %
13.09 %
12.79 %
12.63 %
12.64 %
10.65 %
10.65 %
11.01 %
11.13 %
Government
0.19 %
0.07 %
0.07 %
0.07 %
0.08 %
0.08 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
6.16 %
7.31 %
7.38 %
7.40 %
7.81 %
8.02 %
7.60 %
7.04 %
6.42 %
5.97 %
5.67 %
5.60 %
5.29 %
5.37 %
5.48 %
5.47 %
5.41 %
5.46 %
Others
7.66 %
7.32 %
6.44 %
5.87 %
4.46 %
5.11 %
4.48 %
4.29 %
5.00 %
5.82 %
6.26 %
6.63 %
1.38 %
1.43 %
1.37 %
1.36 %
1.28 %
1.28 %
No of Share Holders
0
2,23,384
3,31,155
3,51,595
3,70,931
4,08,017
4,55,624
4,08,231
3,70,396
3,11,764
2,97,953
3,06,495
2,94,324
3,36,309
3,70,863
3,65,356
3,71,619
3,86,127

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3.2 3.5 3.5 3.5 3.5 2.5 6 3 11
Dividend Yield (%) 0.00 0.85 1.01 1.31 0.79 1 0.51 0.6 0.34 1.12

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
30 Jul 2021 DIVIDEND Dividend
₹ 3.50 /share
28 Jul 2021 628.10 571.90
29 Jul 2022 DIVIDEND Dividend
₹ 2.50 /share
28 Jul 2022 338.75 349.60
28 Jul 2023 DIVIDEND Dividend
₹ 6.00 /share
28 Jul 2023 518.80 649.50
26 Jul 2024 DIVIDEND Dividend
₹ 3.00 /share
26 Jul 2024 1,009.00 1,205.80
09 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Aug 2024 1,009.00 1,279.40
12 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Nov 2024 1,002.20 968.55
05 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Feb 2025 995.50 974.00
20 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
20 May 2025 873.70 911.40
25 Jul 2025 DIVIDEND Dividend
₹ 11.00 /share
25 Jul 2025 902.70 971.05
12 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Aug 2025 969.80 955.50
12 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
12 Aug 2025 911.40 955.50

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media Release1 day ago
Announcement under Regulation 30 (LODR)-Change in Management4 days ago
Intimation Of ESG Rating4 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication10 days ago
Announcement under Regulation 30 (LODR)-Earnings Call Transcript10 days ago
UpdateAug 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 13, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementAug 12, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateAug 12, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 12, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 12, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 12, 2025
Unaudited Financial Results For The Quarter Ended On June 30 2025Aug 12, 2025
Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended On June 30 2025Aug 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 06, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Aug 04, 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended On June 30 2025.Aug 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 29, 2025
Update On AcquisitionJul 29, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 22, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 17, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 16, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 16, 2025
Reg. 34 (1) Annual Report.Jul 16, 2025
Notice Of AGMJul 16, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 15, 2025
Incorporation Of A WOS In The United States Of AmericaJul 12, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 02, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 01, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionJun 27, 2025
Closure of Trading WindowJun 27, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJun 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 18, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 16, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 10, 2025

Technical Indicators

RSI(14)
Neutral
51.22
ATR(14)
Less Volatile
22.82
STOCH(9,6)
Neutral
56.69
STOCH RSI(14)
Neutral
45.31
MACD(12,26)
Bullish
1.19
ADX(14)
Weak Trend
17.50
UO(9)
Bearish
48.42
ROC(12)
Uptrend And Accelerating
2.67
WillR(14)
Neutral
-49.72

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
ICICI Prudential Large Cap Fund Direct-Growth
0.59%
-726470
-0.11%
-0.09%
ICICI Prudential Innovation Fund Direct - Growth
0.00%
-716714
-1.00%
-1.47%
ICICI Prudential Value Direct-Growth
0.44%
-585132
-0.11%
-0.15%
Kotak Manufacture in India Fund Direct - Growth
0.00%
-500000
-1.97%
-2.17%
ICICI Prudential Exports and Services Fund Direct-Growth
0.00%
-288900
-2.00%
-1.93%
Kotak Arbitrage Fund Direct-Growth
0.02%
-268200
-0.04%
-0.04%
ICICI Prudential ELSS Tax Saver Direct Plan - Growth
0.47%
-240158
-0.16%
-0.14%
Parag Parikh Flexi Cap Fund Direct-Growth
1.24%
211950
-0.04%
-0.04%
ICICI Prudential MNC Fund Direct - Growth
2.02%
-73008
-0.45%
-0.32%
Bandhan Business Cycle Fund Direct-Growth
0.31%
-45055
-0.25%
-0.43%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
2.97%
-43890
-0.34%
-1.04%
Invesco India Arbitrage Fund Direct-Growth
0.06%
-40500
-0.02%
-0.06%
Tata Arbitrage Fund Direct - Growth
0.07%
-38700
-0.03%
0.00%
Kotak Healthcare Fund Direct - Growth
1.60%
-35000
-0.91%
-0.86%
Mirae Asset Healthcare Fund Direct - Growth
0.00%
-21721
-0.08%
-0.08%
Edelweiss Arbitrage Fund Direct-Growth
0.02%
-19800
-0.01%
-0.03%
SBI Arbitrage Opportunities Fund Direct-Growth
0.04%
-18000
-0.01%
-0.05%
Nippon India Arbitrage Fund Direct-Growth
0.08%
18000
0.01%
-0.26%
ICICI Prudential Nifty Next 50 Index Direct-Growth
1.04%
12237
0.01%
0.05%
UTI Nifty Next 50 Index Fund Direct - Growth
1.04%
10984
0.01%
0.05%
Bandhan Arbitrage Fund Direct-Growth
0.08%
9000
0.01%
-0.03%
UTI Arbitrage Fund Direct-Growth
0.09%
-8100
-0.02%
-0.11%
ICICI Prudential Equity Arbitrage Direct-Growth
0.06%
-5400
0.00%
0.01%
Kotak Nifty Next 50 Index Fund Direct - Growth
1.04%
3367
0.00%
0.05%
HDFC NIFTY Next 50 Index Fund Direct - Growth
1.04%
3020
0.01%
0.05%

About Zydus Life Science

Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care, and over-the-counter products. Zydus has a global presence, marketing products in the United States, India, Europe, and emerging markets. Key products include Lipaglyn, Bilypsa, Ujvira, Exemptia, Vivitra, and Bryxta, covering areas such as oncology, autoimmune diseases, nephrology, and infectious illnesses. The company has manufacturing facilities in various Indian states and has made several strategic acquisitions and partnerships to expand its product range and market presence.
Listing Date
27 Apr, 2000(25 Years, 3 days)
Chairperson NamePankaj R Patel